Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 4,366.00
+9.00 (0.21%)
Jun 27, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Gastroenterology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gastroenterology Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PDT Immunology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PDT Immunology Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Metabolic | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Metabolic Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Hematology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Hematology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Hereditary Angioedema | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Hereditary Angioedema Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Rare Disease | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
GI Revenue (Post-FY2024 Reporting) | 1,357.02B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
GI Revenue (Post-FY2024 Reporting) Growth | 11.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Revenue (Post-FY2024 Reporting) | 752.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Revenue (Post-FY2024 Reporting) Growth | 9.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PDT Revenue (Post-FY2024 Reporting) | 1,032.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
PDT Revenue (Post-FY2024 Reporting) Growth | 14.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Revenue (Post-FY2024 Reporting) | 560.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Revenue (Post-FY2024 Reporting) Growth | 21.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccines | 55.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccines Growth | 9.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Revenue (Post-FY2024 Reporting) | 565.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Revenue (Post-FY2024 Reporting) Growth | -9.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Revenue (Post-FY2024 Reporting) | 257.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Revenue (Post-FY2024 Reporting) Growth | -18.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 | 1.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Japan | 418.46B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Japan Growth | -7.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 2,379.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 8.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe and Canada | 1,055.25B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe and Canada Growth | 9.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America | 235.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America Growth | 19.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Russia / CIS | 72.36B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Russia / CIS Growth | -0.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographic | 128.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographic Growth | 9.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China | 191.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia (ex-Japan & China) | 99.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia (ex-Japan & China) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|